Advanced Filters
noise
Found 1,843 clinical trials
J Jaeyoung Cho, M.D., Ph.D.

OSA in Never Smokers With Lung Cancer

Previous studies have yielded inconsistent findings regarding the association between obstructive sleep apnea and the prevalence and mortality of lung cancer. Smoking history, a common risk factor for lung cancer, chronic obstructive pulmonary disease, and obstructive sleep apnea, may act as a confounding variable, limiting interpretation of the results. The …

19 - 80 years of age All Phase N/A
B Bastian Eul, MD

Giessen Pulmonary Hypertension in Lung Cancer Registry

The aim of this study is to investigate the frequency and implications of pulmonary hypertension in lung cancer patients. To do so, data will be collected from all lung cancer patients at the university hospital Giessen. All data will be analyzed for possible hints of pulmonary hypertension as a comorbidity …

18 years of age All Phase N/A
J Jia-Tao Zhang, Ph.D

MRD Monitoring in Lung Cancer After Resection

The conception of molecular residual disease (MRD) extending from hematologic tumor to solid tumors. Evidences supporting MRD evaluation for lung cancer by liquid biopsy has gradually accumulated, especially circulating tumor DNA (ctDNA). In this observational study, the investigators prospectively enroll stage I-IIIA non-small cell lung cancer (NSCLC) patients who underwent …

18 years of age All Phase N/A

Using Urine Samples to Identify Lung Cancer

The researchers are doing this study to test the ability of an animal biosensor platform (ABP) to detect NSCLC. Participants in this study will either be diagnosed with NSCLC, suspected to have NSCLC, or have not been diagnosed or suspected to have NSCLC. The ABP test uses laboratory animals that …

18 - 90 years of age All Phase N/A
Z Zoe Davey

Improving Access to Lung Cancer Clinical Trials

There are ~85,000 lung cancer patients (LCPs) in the UK; yet only around 8% were recruited into clinical trials in 2021/22. LCPs need opportunities to take part in clinical trials to access new treatments, increasing their quality of life, treatment choices and life expectancy. Discussions with nurses can help patients …

18 - 65 years of age All Phase N/A
R Robert J. Volk

CPRIT: Patient Adherence to Lung Cancer Screening

To understand participants' barriers to lung cancer screening and their experience with scheduling lung cancer screening.

50 - 80 years of age All Phase N/A

Value-Based Medicine (VBM) for Lung Cancer

This is a prospective observational monocentric trial. The primary endpoint is the validation of predictive models. These predictive models will be used to develop a personalized clinical-functional risk profile for estimating in advance, prior to surgery, the probability for a patient to experience surgical complications, pain, fatigue, dyspnea, as well …

18 years of age All Phase N/A
G Giuseppe Failla, MD

Environmental Pollutants in COPD and Lung Cancer

Epidemiological studies describe a statistically significant correlation between hospitalization rate and exposure to environmental pollutants such as atmospheric particulates (PM10 and PM2.5) and polycyclic aromatic hydrocarbons (PAH). Indeed, they induced the release of inflammation mediators and oxidative stress, involved in remodeling and destruction of the alveolar parenchyma, in turn associated …

18 years of age All Phase N/A
W Wei Dai

Shared Decision Making in Patients With Lung Cancer

The objective of this study is to develop a Decision Aid for Lung Cancer Molecular Testing (DA_LCMT) and to facilitate shared-decision making in patients who were diagnosed with lung adenocarcinoma by intraoperative frozen pathology about whether to conduct the molecular testing.

18 years of age All Phase N/A
M Marissa Rienton-Lim, CCRC

Collection of Sputum and Labeling for Lung Cancer

The primary objective of this study is to compare Assay results to diagnoses determined by currently accepted standards for lung cancer detection. This will be accomplished by analysis of sputum samples from three cohorts including healthy Participants, high risk Participants, and cancer patient Participants using the Assay as developed in …

21 years of age All Phase N/A

Simplify language using AI